What ≥98% Purity Actually Means — and Where It Doesn’t Apply
Not a marketing number. The release specification for our standard synthetic catalogue, with the chromatography to prove it — and production written off when a batch misses it.
The number on the label
“≥98% purity” gets thrown around like it’s a marketing slogan. For us, it’s a hard cutoff — the release specification for our standard synthetic-peptide catalogue, with no rounding up and no relabeling. A small number of products are released against a different, scientifically appropriate specification, and each product page states its own.
If a batch of a standard synthetic peptide comes off the analytical column at 97.4%, it doesn’t get relabeled, discounted, or quietly blended with a cleaner batch to bring the average up. It gets destroyed. We’ve thrown out roughly 7% of everything we’ve synthesised this year for exactly that reason — full production cost absorbed, zero product shipped.

What HPLC actually shows
High-Performance Liquid Chromatography pushes a small, dissolved amount of a peptide sample through a densely packed column under pressure. Different molecules interact with the column packing differently, so they travel through it at different speeds — by the time the sample reaches the detector, the active peptide has separated from anything riding along with it: truncated chains, deletion sequences, leftover solvent, side-reaction byproducts.
The instrument records this as a chromatogram. One tall, sharp peak is your peptide. Smaller peaks on either side are everything else that came off the column. Integrate the area under each peak and you get a percentage — that’s the purity figure printed on the certificate of analysis.
Our analytical runs are performed on Agilent 1260 Infinity II systems with C18 columns, recalibrated against a reference standard every week so results stay consistent and comparable from batch to batch.
Three grades — and the products graded another way
Not every application needs the same purity ceiling, and not every molecule is released on an HPLC percentage at all. The three graded tiers are verified with the same analytical process — only the cutoff and the availability change.
| Grade | Purity | Available for |
|---|---|---|
| Research-Grade | ≥98% | The standard synthetic-peptide catalogue — 80 of our 99 products |
| Premium-Grade | ≥99% | On request — for assay-sensitive work |
| Reference-Grade | ≥99.9% | Custom synthesis only — usually for analytical labs calibrating their own instruments |
| Method-specific | SDS-PAGE, IU bioassay, or monograph grade | Recombinant proteins, gonadotropins and complex extracts, where a single HPLC percentage is not the right release basis — stated on each product page |
Why we don’t quote one purity floor for everything
A lot of catalogues quote one purity floor — usually 95% — across everything they list, whatever the molecule. On paper, 5% impurity doesn’t sound like much. In practice, it’s a bigger deal than the number suggests.
That 5% is usually a mix of truncated peptides — your sequence missing one or two amino acids — and deletion products formed during synthesis. Some of those byproducts are pharmacologically active in their own right. So a “BPC-157” sample at 95% purity isn’t just BPC-157 plus inert filler; it’s also delivering some BPC-13, BPC-14, and similar truncated variants, at ratios nobody has told you.
That’s why ≥98% is the floor for standard synthetic peptides: the smaller the byproduct pool, the less it can confound the variable you’re actually testing.
It’s also why one blanket number across an entire catalogue is a tell: it says the vendor never asked what the right specification for each molecule is.
And for some molecules a purity percentage isn’t the right release basis at all. ACE-031 and GDF-8 (myostatin) are recombinant proteins, released on SDS-PAGE. HMG is a gonadotropin, standardised by bioassay and expressed in International Units. Dulaglutide is a glycosylated Fc-fusion protein, characterised by size and charge-variant profiling rather than by integrating one peak. Cerebrolysin, Cerebroneurogen, Actovegin and Thymalin are peptide mixtures and extracts, where a single-compound purity figure describes nothing. Each of those product pages states the specification the product is actually released against.
What HPLC won’t tell you — and what we run instead
Purity isn’t identity. A 99%-pure peak can still be 99% of the wrong peptide. So identity is confirmed independently, and every batch clears further checks before it’s cleared to ship.
Mass spectrometry
Confirms the molecular weight of the peak matches the theoretical value for the target sequence — catching anything HPLC alone could mistake for your peptide.
Sequence verification
Confirms the amino acids are in the correct order, not just the correct overall composition — two peptides can share a molecular weight and still not be the same molecule.
Endotoxin assay
Run via LAL (Limulus Amebocyte Lysate) test on request and for flagged products, screening for bacterial endotoxin contamination — the certificate of analysis states whether it was performed on your lot.
Related resources
Our quality control processHow a batch moves from synthesis to shipped, and every checkpoint in between.
Storage guideHow to store peptides so they stay at the purity they arrived at.
Peptide libraryBrowse the full catalogue, grade by grade.
Every batch, verified four ways.
Browse research peptides synthesised to a ≥98% purity minimum across the standard catalogue — HPLC-tested, mass spec-confirmed, with the release specification stated on every product page.